PTC THERAPEUTICS, INC. 4

Chief Technical Ops Officer Neil Gregory Almstead exercised 2,464 options and sold 2,464 PTC Therapeutics common shares on 2026-07-09 under a Rule 10b5-1 plan.

On July 9, 2026, PTC Therapeutics, Inc. Chief Technical Ops Officer Neil Gregory Almstead exercised 2,464 stock options at $46.54 per share and immediately sold the same 2,464 common shares at a weighted average price of $90.25 per share under a Rule 10b5-1 trading plan, realizing an implied spread of roughly $108,000, while his spouse separately holds 2,899 shares indirectly; following these transactions, Almstead reported direct ownership of 60,299 common shares, indirect ownership of 2,899 shares via his spouse, and 45,036 options remaining exercisable. The transaction appears to be a routine, pre-planned option exercise-and-sale for liquidity and tax/monetization rather than an open-market discretionary trade.

Filing Facts

CIK

1070081

Ticker

PTCT

Form

4

Source Type

fda

Accession

0001578850-26-000023

Alert Tier

6